FORADIL AEROLIZER

Compare FORADIL AEROLIZER  to:
Compare
Compare

Generic Name for FORADIL AEROLIZER

Formoterol fumarate 12 micrograms/inh; dry pwd in caps for inhalation; with inhaler device.

Legal Classification:

Rx

Pharmacological Class for FORADIL AEROLIZER

Long-acting β2-agonist.

Manufacturer of FORADIL AEROLIZER

Schering Corporation

Indications for FORADIL AEROLIZER

As an adjunct (see literature): For the maintenance treatment of asthma and in the prevention of bronchospasm in reversible obstructive airway disease (including nocturnal asthma). Maintenance treatment of COPD-associated bronchospasm. Prevention of exercise-induced bronchospasm (EIB).

Adults and Children:

<5 years: not recommended. ≥5 years: 1 inh (12 micrograms) every 12 hours. Prevention of EIB: 1 inh at least 15 minutes before exercise (do not use additional doses for EIB if already using regular dosing for asthma).

Contraindications for FORADIL AEROLIZER

Not for treatment of acute attacks or when occasional use of short-acting drugs suffices. Do not initiate in significantly worsening or acutely deteriorating asthma. Formoterol is not a substitute for steroids. Do not exceed recommended dose.

Precautions for FORADIL AEROLIZER

Not for use with other long-acting β2-agonists. Cardiovascular disease (esp. hypertension, coronary insufficiency, arrhythmias). Convulsive disorders. Thyrotoxicosis. Hyperresponsiveness to sympathomimetics. Evaluate response before altering steroid doses (may still need an antiinflammatory). Prescribe a short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Do not use with spacers. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.

Interactions for FORADIL AEROLIZER

Avoid MAOIs, tricyclic antidepressants, drugs that prolong QTc. Hypokalemia potentiated by xanthines, steroids, or diuretics. Antagonized by β-blockers.

Adverse Reactions for FORADIL AEROLIZER

Infection, tremor (skeletal muscle), dizziness, insomnia, dysphonia, tonsillitis, paradoxical bronchospasm, β2-agonist effects (eg, hypo- or hypertension, angina, tachycardia, arrhythmias, nervousness, hypokalemia, hyperglycemia, metabolic acidosis); rarely: serious asthma episode, asthma-related death.

How is FORADIL AEROLIZER supplied?

Caps—12, 60

Related Disease:

Asthma~antiasthmatics
Bronchospasm~bronchodilators
COPD {COPD}

Related Resources

Orphan drug designation granted for aerosolized alpha1-proteinease inhibitor for alpha1-antitrypsin deficiency

February 08, 2010

Talecris Biotherapeutics was granted orphan drug designation by the FDA for the development of an aerosol formulation of alpha1-proteinease inhibitor to treat congenital alpha1-antitrypsin (AAT) deficiency.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Spiriva HandiHaler safety update

January 15, 2010

The FDA announced that data from a recent review of Spiriva HandiHaler (tiotropium dry powder for inhalation, from Boehringer Ingelheim) do not support an increased risk of stroke, heart attack, or death.

Spiriva HandiHaler approved for the reduction of COPD exacerbations

December 21, 2009

Spiriva HandiHaler (tiotropium powder for oral inhalation, from Boehringer Ingelheim and Pfizer) has been approved by the FDA for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).

Concentrated Prolastin-C approved for alpha1-antitrypsin (AAT) deficiency

October 19, 2009

The FDA has approved Prolastin-C (alpha1-proteinase inhibitor [human], from Talecris Biotherapeutics), a more concentrated formulation of Prolastin, for the treatment of alpha1-antitrypsin (AAT) deficiency.